CD8A and neoplasm: Single-cell therapy with day-10 CD8+ CTLs moderately suppressed tumour growth without inducing tumour-free survival; whereas treatment with day-20 cells resulted in complete tumour regression in 20% of the B16-OVA-bearing mice (Figure 1c).